Published online Apr 28, 2020. doi: 10.13105/wjma.v8.i2.54
Peer-review started: December 29, 2019
First decision: February 29, 2020
Revised: March 26, 2020
Accepted: April 15, 2020
Article in press: April 15, 2020
Published online: April 28, 2020
Core tip: The clinical management of ulcerative colitis and Crohn’s disease represent a major challenge in the gastroenterology field since conventional therapies present several limitations. Interestingly, changes in gut microbiota are linked to the development of these diseases. In this sense, the use of probiotics becomes a plausible alternative for treating affected individuals. Although several microorganisms have been tested for this purpose, satisfactory results have been obtained only with a portion of them. Therefore, this minireview aims to explore the role of microbiota in the pathogenesis of inflammatory bowel disease and to compile the most concrete data on probiotics efficiency in its treatment.